Today: 8 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 24 December 2025 - 6 January 2026

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics shares fell 3.3% to $35.61 by early afternoon Tuesday, underperforming biotech peers as investors awaited updates on its blood-pressure drug lorundrostat. The stock remains up 183% over 52 weeks but is down 25% from its November high. Mineralys plans to file for FDA approval of lorundrostat by early 2026 and expects Phase 2 results in the first quarter of that year.
30 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly shares closed at $1,077.75 Friday, near record highs, as U.S. markets shut for the weekend. ABL Bio announced $55 million in new funding tied to Lilly, including a $40 million upfront payment and $15 million equity investment. Investors remain focused on obesity-drug momentum and the FDA’s recent approval of Novo Nordisk’s weight-loss pill.
28 December 2025
·
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie closed Friday at $229.98, near its 52-week high, as U.S. markets ended a quiet post-holiday session with major indexes little changed. No major AbbVie corporate news broke in the past two days, but investor analysis and institutional filings kept the stock in focus. Institutions and hedge funds hold about 70% of shares. The next regular trading session is Monday.
27 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences shares fell 0.74% to $18.12 late Thursday morning, underperforming the broader market as biotech stocks slipped. Earlier this month, Wave reported positive Phase 1 data for its obesity drug candidate WVE-007 and raised $402.5 million in an upsized equity offering, extending its cash runway into Q3 2028.
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly shares closed at $1,076.98 after the early NYSE close on Dec. 24, with after-hours quotes near $1,077–$1,078 in thin holiday trading. U.S. exchanges remained shut Dec. 25 for Christmas. The 52-week range stands at $623.78 to $1,111.99. Trading volume is expected to rise when markets reopen Friday, with attention on GLP-1 policy and competition.
25 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb closed at $54.71 on Dec. 24, 2025, after trading between $54.20 and $54.75, with a 52-week range of $42.52 to $63.33. The company agreed to provide Eliquis free to Medicaid starting in 2026 and will donate over seven tons of Eliquis API to the U.S. government. BMS also announced steep discounts for several drugs and secured three years of tariff relief.
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb closed at $54.71 on Dec. 24, up 0.79%, with after-hours trading flat at $54.70 amid thin holiday volume. The NYSE session ended early for Christmas Eve. Analysts cited by MarketBeat maintained a “Hold” consensus and average 12-month target near current levels. No major company news moved the stock.
25 December 2025
··
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.
24 December 2025
··
1 2 3 4 5 … 8

Stock Market Today

Adobe stock (ADBE) slips into the weekend — what traders watch before Monday

Adobe stock (ADBE) slips into the weekend — what traders watch before Monday

8 February 2026
Adobe shares closed down 0.4% at $268.38 Friday, trailing a broader tech rally that sent the Dow above 50,000 for the first time. Semrush shareholders approved a merger with Adobe, advancing the $1.9 billion deal. Investors await key U.S. jobs and inflation data this week. Adobe’s next earnings report is expected in mid-March.
Snowflake stock snaps back with 7% jump — what to watch before Monday

Snowflake stock snaps back with 7% jump — what to watch before Monday

8 February 2026
Snowflake shares jumped 7.5% to $168.43 Friday, tracking a late-week tech rebound. Director Michael L. Speiser sold 50,741 shares on Feb. 6 under a pre-set plan, according to a regulatory filing. The company recently announced a $200 million partnership with OpenAI. Snowflake reports earnings Feb. 25.
Go toTop